Determining overdiagnosis by screening with DRE/TRUS or PSA (Florence pilot studies, 1991–1994)

This publication has 12 references indexed in Scilit:

• Lead Times and Overdetection Due to Prostate-Specific Antigen Screening: Estimates From the European Randomized Study of Screening for Prostate Cancer
  JNCI Journal of the National Cancer Institute, 2003
• Overdiagnosis Due to Prostate-Specific Antigen Screening: Lessons From U.S. Prostate Cancer Incidence Trends
  JNCI Journal of the National Cancer Institute, 2002
• Large‐scale randomized prostate cancer screening trials: Program performances in the European randomized screening for prostate cancer trial and the prostate, lung, colorectal and ovary cancer trial
  International Journal of Cancer, 2001
• Re: Prostate Cancer Incidence and Mortality in the United States and the United Kingdom
  JNCI Journal of the National Cancer Institute, 2001
• Determination of county-level prostate carcinoma incidence and detection rates with medicare claims data
  Cancer, 2001
• Prostate cancer screening: the problem of overdiagnosis and lessons to be learned from breast cancer screening
  European Journal Of Cancer, 2000
• Urinary and Sexual Function After Radical Prostatectomy for Clinically Localized Prostate Cancer
  JAMA, 2000
• Rationale for randomised trials of prostate cancer screening
  European Journal Of Cancer, 1999
• Overdiagnosis of prostate carcinoma by screening: An estimate based on the results of the Florence Screening Pilot Study
  Annals of Oncology, 1998
• The role of prostate-specific antigen (PSA) testing patterns in the recent prostate cancer incidence declinein the United States
  Cancer Causes & Control, 1998